I Asked AI to Count My Carbs 27,000 Times. It Couldn’t Give Me the Same Answer Twice.
Ask ChatGPT to estimate the carbs in your lunch. Now ask it again. And again. Five hundred times. You’d expect the same answer each time. […]
Blog Posts
The Daily Bolus: The Triple Agonist Showdown & Surprising GLP-1 Wins in Type 1 Diabetes
Welcome to today’s edition of The Daily Bolus! The incretin landscape is rapidly evolving into the era of the “triple agonist,” with Eli Lilly and […]
100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure
Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn’t it a cure yet, and how does it fit into the actual blueprint of a functional cure?
Explore a Decade of Diabetes Insights with Diabettech AI
After 10+ years of documenting the diabetes landscape, Diabettech is launching diabettech.ai—a custom research tool designed to help you navigate a decade’s worth of articles and reports. Powered by an LLM interface, this tool allows you to “interrogate” the site’s data to find specific answers on everything from cures to n=1 observations.
Key highlights of the beta launch:
Targeted Accuracy: Built to stick strictly to Diabettech articles and comments to minimize “hallucinations.”
Research-Focused: Optimized as a precision tool rather than a standard chatbot to provide relevant article links.
Sustainable Design: Privately funded and optimized for efficiency to manage resource costs and query speeds.
Ready to dive into the archives? Visit diabettech.ai to start your research and share your feedback on the beta experience.
The Daily Bolus: Red Cell Sponges, Microbiome Signatures, and Cyborg Cells
Today’s research is moving beyond the traditional “big three” of glucose disposal—liver, muscle, and fat. We explore how red blood cells can be recruited as metabolic “sponges,” how AI-driven gut signatures are catching insulin resistance earlier than ever, and why an electronic “cyborg” mesh might be the key to making lab-grown pancreatic cells finally function like the real thing. It’s a steady shift toward an integrated, multi-system approach to metabolic health.
Now We Know What a Type 1 Cure Could Look Like
The Type 1 cure is no longer theoretical. Human data now points to a blueprint: working cells, immune evasion, and durable immune modulation.
The Daily Bolus: Retinopathy Pills, Diabetes Risk Watches, and Immune Fixes for Insulin Resistance
The diabetes pipeline is starting to look a lot like the cardiovascular playbook: prevent early, intervene earlier, and push treatment upstream before irreversible damage begins. […]
The Daily Bolus: Early Warnings, Genetic Cloaks, and the Seven-Year Shield
Whilst the title of this edition sounds like something out of science fiction, in it we see a masterclass in “biological intelligence.” As of February […]
The Daily Bolus: Mechanism over metrics, biology over dashboards
The developments highlighted in the bolus today reinforce a theme Diabettech has been circling for years: the most meaningful progress in diabetes does not come […]
The Daily Bolus: Et tu, B Cells?
Recent news has been defined by a pivot toward “biological intelligence.” As of January 21, 2026, the signal cutting through the noise isn’t just about […]